• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Procaps Group S.A.

    2/14/22 1:49:59 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PROC alert in real time by email
    SC 13G 1 d289838dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.         )*

     

     

    PROCAPS GROUP S.A.

    (Name of Issuer)

    Ordinary Shares, nominal value $0.01 per share

    (Title of Class of Securities)

    L7756P102

    (CUSIP Number)

    September 29, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☒

    Rule 13d-1(c)

     

    ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. L7756P102   13G   Page 2 of 5

     

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

      1.    

    Names of Reporting Persons.

     

    International Finance Corporation (IFC)**

    98-000-2550

        **IFC is an international organization established by Articles of Agreement among its member countries, and as such, enjoys certain immunities, privileges and exemptions, including the freedom of all of its property and assets from restrictions, regulations, controls and moratoria of any nature. The voluntary provision by IFC of the information contained in this document does not in any way constitute or imply a waiver, termination or modification by IFC of any privilege, immunity or exemption of IFC granted in the Articles of Agreement establishing IFC, international conventions, or applicable law.
      2.    

    Check the Appropriate Box if a Member of a Group

    (a)  ☐        (b)  ☐

     

      3.    

    SEC Use Only

     

      4.    

    Citizenship or Place of Organization: International Organization established by Articles of Agreement among its Member Countries.

     

    Number of

    Shares

    Beneficially  

    Owned by

    Each

    Reporting

    Person

    With:

         5.     

    Sole Voting Power

     

    9,492,427 shares

         6.     

    Shared Voting Power

     

    N/A

         7.     

    Sole Dispositive Power

     

    9,492,427 shares

         8.     

    Shared Dispositive Power

     

    N/A

      9.    

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    9,492,427

      10.    

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    N/A

      11.    

    Percent of Class Represented by Amount in Row (9)

     

    8.41%

      12.    

    Type of Reporting Person:

     

    00


    CUSIP No. L7756P102   13G   Page 3 of 5

     

    ITEM 1.   
      (a)   Name of Issuer: Procaps Group S.A.
               (b)   Address of Issuer’s Principal Executive Offices: 9, rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg
    ITEM 2.
      (a)   Name of Person Filing: Raphaël Eskinazi
      (b)   Address of Principal Business Office, or if None, Residence: Carrera 7 #71-21,Torre A, Piso 14, Bogota D.C., Colombia
      (c)   Citizenship: French
      (d)   Title of Class of Securities: Ordinary Shares
      (e)   CUSIP Number: L7756P102
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
    (a)   [    ]      Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b)   [    ]      Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)   [    ]      Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)   [    ]     

    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

    (e)   [    ]      An investment adviser in accordance with ss.240.13d-1(b)(1)(ii)(E);
    (f)   [    ]      An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F);
    (g)   [    ]      A parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G);
    (h)   [    ]      A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)   [    ]      A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)   [    ]      Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).

    ITEM 4. OWNERSHIP.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)

    Amount beneficially owned: 9,492,427 Ordinary Shares

     

      (b)

    Percent of class: 8.41%

     

      (c)

    Number of shares as to which such person has: 9,492,427 Ordinary Shares

     

      (i)

    Sole power to vote or to direct the vote Yes

     

      (ii)

    Shared power to vote or to direct the vote N/A

     

      (iii)

    Sole power to dispose or to direct the disposition of 9,492,427 Ordinary Shares

     

      (iv)

    Shared power to dispose or to direct the disposition of N/A

     


        Page 4 of 5

     

    INSTRUCTION. For computations regarding securities which represent a right to acquire an underlying security SEE ss.240.13d3(d)(1).

    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    INSTRUCTION: Dissolution of a group requires a response to this item.

    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

    If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

    If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

    ITEM 9. NOTICE OF DISSOLUTION OF GROUP.

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

    ITEM 10. CERTIFICATIONS.

     

      (a)

    The following certification shall be included if the statement is filed pursuant to Rule 13d-1(b):

    “By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.”

     

      (b)

    The following certification shall be included if the statement is filed pursuant to Rule 13d-1(c):

    “By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.”


        Page 5 of 5

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    February 11, 2022

    (Date)

     
     

    /s/ Raphaël Eskinazi

     
      (Signature)  
      Raphaël Eskinazi, Portfolio Manager  
     

    Manufacturing, Agribusiness and Services Department Latin America and the Caribbean

    (Name/Title)

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Get the next $PROC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PROC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PROC
    SEC Filings

    View All

    SEC Form 6-K filed by Procaps Group S.A.

    6-K - Procaps Group, S.A. (0001863362) (Filer)

    2/19/25 8:56:19 AM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Procaps Group S.A.

    6-K - Procaps Group, S.A. (0001863362) (Filer)

    2/3/25 9:00:03 AM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Procaps Group S.A.

    6-K - Procaps Group, S.A. (0001863362) (Filer)

    1/16/25 8:30:04 AM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PROC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3: New insider Manieu Alexandre Weinstein claimed ownership of 15,877,516 units of Ordinary Shares

    3 - Procaps Group, S.A. (0001863362) (Issuer)

    10/12/21 9:32:55 AM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3: New insider Minski Ruben claimed ownership of 31,338,454 units of Ordinary Shares

    3 - Procaps Group, S.A. (0001863362) (Issuer)

    10/8/21 5:22:21 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3: New insider Minski Jose claimed ownership of 17,960,146 units of Ordinary Shares

    3 - Procaps Group, S.A. (0001863362) (Issuer)

    10/8/21 5:20:55 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PROC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Procaps Group Receives Delisting Notice From Nasdaq

    MIAMI and BARRANQUILLA, Columbia, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that the Company received a notice from The Nasdaq Stock Market LLC ("Nasdaq") that it has determined to delist the Company's ordinary shares on Nasdaq. The delisting is a result of the Company's failure to demonstrate compliance with Nasdaq Listing Rules 5250(c)(1) and 5250(c)(2) for failing to file periodic and interim financial reports. As a result of the forgoing, the Company's ordinary shares are expected to commence trading on the Expert Market operated by the OTC

    2/3/25 8:50:00 AM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Procaps Group Receives Additional Delinquency Letter

    MIAMI and BARRANQUILLA, Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that, as anticipated, on December 31, 2024, the Company received notice from The Nasdaq Stock Market LLC ("Nasdaq") of an additional filing delinquency relating to the Company's interim financial statements for the period ended June 30, 2024. The interim financial statements were required to be filed with Nasdaq by December 31, 2024, but were not for the reasons previously disclosed in connection with the delay in the filing of the Company's Form 20-F for the fiscal yea

    1/3/25 4:15:00 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates

    MIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team. The Shareholders Meeting marked an important milestone with the election of new members to the Board of Directors. The newly elected members bring a diverse range of expertise and strategic insight to guide Procaps' future growth. Newly app

    12/20/24 4:53:03 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PROC
    Financials

    Live finance-specific insights

    View All

    Procaps Group Reports Third Quarter 2023 Results

    Net Revenues Increased 5% in 9M23 Year-over-Year on a Constant Currency Basis, Driven by 13% RX Growth Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated international healthcare and pharmaceutical services company, today announced its financial results for the three months ended September 30, 2023 ("3Q23") and the nine months ended September 30, 2023 ("9M23"). Financial Highlights 3Q23 & 9M23 Net revenues totaled $118 million for 3Q23, positively impacted by the performance of RX and OTC portfolios, offset by lower CDMO revenues. On a constant currency basis, net revenues increased by 2% in 3Q23. For 9M23, net revenues totaled $313 million, an incre

    12/26/23 5:40:00 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Procaps Group Update on Third Quarter Results

    Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it is postponing the previously-announced earnings conference call (currently scheduled for November 16, 2023) to a later date after Procaps publishes its results for the third quarter and nine months ended September 30, 2023 ("3Q23"). Procaps will host a conference call in conjunction with its release of the 3Q23 Results, and call/webcast details will be provided in advance of the call. About Procaps Group Procaps Group, S.A. ("Procaps") (NASDAQ:PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplie

    11/14/23 5:25:00 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Procaps Group to Report Third Quarter and Nine Months 2023 Results on Tuesday November 14, 2023

    Company to Host Conference Call on Thursday November 16, 2023 at 10:30 a.m. Eastern Time Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical services company, announced it will report its results for the third quarter and nine months ended September 30, 2023, after market closes on Tuesday, November 14, 2023. The Company will host a conference call and webcast on Thursday, November 16, 2023, at 10:30 a.m. Eastern time, to discuss the third quarter and nine months 2023 results. To access the call, please use the following information: Date: Thursday, November 16, 2023 Time: 10:30 a.m. ET Webcast: Cli

    11/10/23 11:37:00 AM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PROC
    Leadership Updates

    Live Leadership Updates

    View All

    Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates

    MIAMI and BARRANQUILLA, Colombia, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced significant outcomes from its recent Shareholders Meeting and subsequent Board of Directors meeting. These include changes to the Board composition, restructuring of Board committees, and updates to its executive leadership team. The Shareholders Meeting marked an important milestone with the election of new members to the Board of Directors. The newly elected members bring a diverse range of expertise and strategic insight to guide Procaps' future growth. Newly app

    12/20/24 4:53:03 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Statement from the Board of Directors of Procaps Group

    Procaps Group (NASDAQ:PROC) ("Procaps"). Having completed the last ordinary meeting of 2023 on December 19th in which Ruben Minski acted as CEO of the Procaps Group for the last time, and taking into account that as of January 15th, 2024 he will take over as Executive Chairman of the Board, which resulted from a planned and communicated process to the market since February of this year, we would like to express our appreciation to Ruben for his inspiring and visionary leadership that has allowed Procaps to be a leading organization in the pharmaceutical sector in the Region today, recognized and valued in the market by the different stakeholders. Throughout his career in the Organization,

    12/21/23 6:45:00 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024

    Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today a strategic leadership transition as Ruben Minski, founder and CEO of Procaps prepares to transition from the role of Chief Executive Officer to focus exclusively on his role as Executive Chairman of the Board, and the appointment of Jose Antonio Vieira as the new Chief Executive Officer of Procaps Group. The transition will be effective January 15, 2024. After over 45 years of visionary leadership and dedicated service, Ruben Minski has played a pivotal role in Procaps' growth and success, transforming it into a global leader in pharmaceutical innovation. Under

    11/22/23 8:30:00 AM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PROC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

    SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

    12/3/24 7:20:10 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

    SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

    10/29/24 9:46:26 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.

    SC 13D/A - Procaps Group, S.A. (0001863362) (Subject)

    10/28/24 8:42:14 PM ET
    $PROC
    Biotechnology: Pharmaceutical Preparations
    Health Care